No abstract available
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Cancer Survivors
-
Central Nervous System Neoplasms* / drug therapy
-
Central Nervous System Neoplasms* / mortality
-
Dacarbazine / administration & dosage
-
Dacarbazine / therapeutic use
-
Female
-
Follow-Up Studies
-
Humans
-
Lymphoma / drug therapy
-
Lymphoma / mortality
-
Maintenance Chemotherapy
-
Male
-
Middle Aged
-
Temozolomide* / therapeutic use
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Alkylating
-
Dacarbazine
-
Temozolomide
Grants and funding
Funding: This work was funded by grants from Nordic Cancer Union, Norpharma, Roche, Schering-Plough, and Inge og Jørgen Larsens Mindelegat.